Category: Today’s Highlights
Vertex has good news from Australia. Why selling solid firms stocks.
Vertex Pharmaceuticals (VRTX) announced that the Pharmaceutical Benefits Advisory Committee’s (PBAC) in Australia recommendation the listing of Orkambi ® (lumacaftor/ivacaftor) on the Pharmaceutical Benefits Scheme (PBS). The recommendation is for cystic fibrosis people ages six and over who have two...
Read More
August 21, 2018
0
Nektar presentation today at the ASCO genitourinary cancers symposium
Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at Moscone West in San Francisco, CA, Nektar (NKTR) will present preliminary efficacy, safety and immune monitoring data from the ongoing metastatic urothelial carcinoma (mUC)...
Read More
February 15, 2019
0
Starting the gene therapy chapter in the book of the biotech revolution
WE ARE LIVING AN HISTORIC BIOLOGICAL REVOLUTION . Unfortunately, the undeniably outstanding news has not yet penetrated the ears of many investors. They are still falling victim to the stock market traders’ games and to critics’ and bloggers’ magnifications or...
Read More
August 22, 2018
0
Amgen Outperformed and Will Continue to Outperform
Amgen’s (AMGN) stock outperformed in the past 6 months for significant reasons and these reasons are still there as we observed listening to the firm’s quarterly results. The firm’s results surpassed analysts’ expectations. The stock outperformed because the firm outperformed,...
Read More
July 26, 2017
0
Reasons for Vertex's & Illumina's Outperformance
Synopsis Most of the Prohost picked stocks gained momentum and closed higher at the end of the week. Some rallied because that’s what they were supposed to do after the quarterly financial when most biotech stocks are subjected to selloffs,...
Read More
August 7, 2017
0
Cytokinetics' heart failure drug omecamtiv mecarbil advancing into late phase trials
Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil , the firm’s potential treatment for heart failure with reduced ejection fraction, is advancing in a late phase clinical trial. Cytokinetics is conducting METEORIC-HF clinical trial, in collaboration with Amgen (AMGN),...
Read More
February 23, 2019
0
Stocks' Declines That Offer Real Opportunities for Accumulation at Bargain Prices
AFTER MANY OF THE PROHOST PICKED STOCKS NEARED REACHING THE PROHOST NEAR-TERM TARGETS, recently, external circumstances and exaggerated delaying news, some of our rallied stocks gave back some of their gains. Two reasons were behind the decline in some precious...
Read More
August 15, 2017
0
Why Sangamo Rallied
About Our New Section On Sunday, August 20, 2017 we will post our first “The Week in Review” article. This current week has carried bad news, political hypocrisy and a catastrophic terrorist attack on the people of Spain. The week...
Read More
August 18, 2017
0
About Portola
Portola (PTLA) has two important approved breakthrough products and an investigational product having promising results on very difficult-to-treat cancers . Instead of soaring following the approval of its two drugs and the good results coming from the investigational third drug,...
Read More
August 27, 2018
0
Why CRISPR Therapeutics' stock gained around $8 today
CRISPR Therapeutics' (CRSP) s tock added around $8 today while reporting financial results for the fourth quarter and full year ended December 31, 2018. Here is what Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, has stated, “This past year...
Read More
February 25, 2019
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)